Skip to main content
SpringerLink
Log in
Book cover

Anaphylaxis and Hypersensitivity Reactions pp 209–222Cite as

Hymenoptera-Induced Hypersensitivity Reactions and Anaphylaxis

  • Chapter
  • First Online:

Abstract

Most Hymenoptera (honeybees, bumblebees, yellow jackets, hornets, wasps and fire ants) stings lead to a local reaction. Up to 7% of population develops systemic allergic reaction to the constituents of venom. Up to 0.5 per one million people die per year due to Hymenoptera venom allergy. Risk factors for the most severe reactions are advanced age, concomitant cardiovascular diseases, concomitant treatment with beta-blockers or angiotensin-converting enzyme inhibitors, mastocytosis, and European hornet (V. crabro) allergy. In a patient presenting with a history of Hymenoptera-induced reactions, the severity of the reaction should be assessed, and responsible insect should be identified. Both answers are critical when specific venom immunotherapy (VIT) is considered for treatment. VIT is the only effective treatment for the prevention of serious allergic reactions to Hymenoptera stings in sensitized individuals. Contraindications for VIT are not as strict as they are for respiratory allergic diseases. In patients at high risk for anaphylaxis, VIT should be done under careful supervision even if it is not possible to take the patient off beta-blockers. VIT is safe and effective in patients with a malignant disease in remission and in autoimmune diseases. The optimal duration of VIT is 5 years. Longer or even lifelong treatment should be considered in patients with systemic mastocytosis, near death anaphylaxis, patients with systemic allergic reactions to immunotherapy injections or stings during VIT and highly exposed patients, such as beekeepers. Nearly complete tolerance is established after only a few days of rush immunotherapy. Long-term effectiveness after stopping immunotherapy is less reliable. In patients with venom induced anaphylaxis, mastocytosis should be actively investigated by testing the baseline serum tryptase level and by a clinical examination searching for characteristic skin lesions. VIT in those patients is associated with a higher rate of severe side effects. VIT is recommended for life because there are some case reports of fatal reactions after stopping venom immunotherapy.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Mueller UR. Insect sting allergy. Stuttgart: Gustav Fisher; 1990.

    Google Scholar 

  2. Winningham KM, Fitch CD, Schmidt M, et al. Hymenoptera venom protease allergens. J Allergy Clin Immunol. 2004;114:928–33.

    Article  PubMed  CAS  Google Scholar 

  3. Hoffman DR. Hymenoptera venom allergens. Clin Rev Allergy Immunol. 2006;30:109–128.

    Article  PubMed  CAS  Google Scholar 

  4. Bilo` BM, Bonifazi F. Epidemiology of insect-venom anaphylaxis. Curr Opinion Allergy Clin Immunol. 2008;8:330–337.

    Article  Google Scholar 

  5. Münstedt K, Hellner M, Winter D, et al. Allergy to bee venom in beekeepers in Germany. J Investig Allergol Clin Immunol. 2008;18:100–105.

    PubMed  Google Scholar 

  6. Kampelmacher MJ, van der Zwan JC. Provocation test with a living insect as a diagnostic tool in systemic reactions to bee and wasp venom: a prospective study with emphasis on the clinical aspects. Clin Allergy. 1987;17:317–327.

    Article  PubMed  CAS  Google Scholar 

  7. Settipane GA, Chafee FH. Natural history of allergy to Hymenoptera. Clin Allergy. 1979;9:385–390.

    Article  PubMed  CAS  Google Scholar 

  8. Ruëff F, Przybilla B, Biló MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol. 2009;124:1047–1054.

    Article  PubMed  Google Scholar 

  9. Antonicelli L, Bilò MB, Napoli G, et al. European hornet (Vespa crabro) sting: a new risk factor for life-threatening reaction in hymenoptera allergic patients? Eur Ann Allergy Clin Immunol. 2003;35:199–203.

    PubMed  CAS  Google Scholar 

  10. Golden DB, Kagey-Sobotka A, Norman PS, et al. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med. 2004;351:668–674.

    Article  PubMed  CAS  Google Scholar 

  11. Mueller HL. Diagnosis and treatment of insect sensitivity. J Asthma Res. 1966;3:331–333.

    Article  PubMed  CAS  Google Scholar 

  12. Rekik S, Andrieu S, Aboukhoudir F, et al. ST elevation myocardial infarction with no structural lesions after a wasp sting. J Emerg Med. 2009 Mar 26;doi:10.1016/j.jemermed.2009.02.019 DOI:dx.doi.org.

  13. Sinkiewicz W, Sobański P, Bartuzi Z. Allergic myocardial infarction. Cardiol J. 2008;15:220–225.

    PubMed  Google Scholar 

  14. Sasvary T, Müller U. Fatalities from insect stings in Switzerland 1978 to 1987. Schweiz Med Wochenschr. 1994;124:1887–1894.

    PubMed  CAS  Google Scholar 

  15. Müller UR. Cardiovascular disease and insect sting anaphylaxis. Handouts of EAACI Congress, Warsaw; 2009.

    Google Scholar 

  16. Prado M, Quirós D, Lomonte B. Mortality due to Hymenoptera stings in Costa Rica, 1985-2006. Rev Panam Salud Publica. 2009;25:389–393.

    Article  PubMed  Google Scholar 

  17. Hoffman DR. Fatal Reactions to Hymenoptera Stings. Allergy Asthma Proc. 2003;24:123–127.

    PubMed  Google Scholar 

  18. Light WC. Insect sting fatality 9 years after venom treatment. J Allergy Clin Immunol. 2001;107:925.

    Article  PubMed  CAS  Google Scholar 

  19. CD Oude Elberink JNG, de Monchy JGR, Kors JW, et al. Fatal anaphylaxis after a yellow jacket sting in two patients with mastocytosis. J Allergy CIin Immunol. 1997;99:153–154.

    Google Scholar 

  20. Korosec P, Silar M, Kopac P, et al. Low sensitivity of venom skin prick tests in patients with severe anaphylactic reactions to hymenoptera stings. Allergy. 2009;64(Suppl. 90):341.

    Google Scholar 

  21. Sturm G, Kranzelbinder B, Schuster C, et al. Correlation of the basophil activation test (BAT) and routine diagnostic tools with the outcome of sting challenges in asymptomatically sensitised subjects to hymenoptera venom. Allergy. 2009;64(Suppl.90):39.

    Google Scholar 

  22. Jeep S, Reiprich G, Kunkel G. Comparison of skin prick tests and intradermal tests with three diflerent yellow jacket venom extracts. Allergy. 1992;47:35–40.

    Article  PubMed  CAS  Google Scholar 

  23. Mari A, Iacovacci P, Afferni C. et al. Specific IgE to cross-reactive carbohydrate determinants strongly affect the in vitro diagnosis of allergic diseases. J Allergy Clin Immunol. 1999;103:1005–1011.

    Article  PubMed  CAS  Google Scholar 

  24. Peternelj A, Silar M, Bajrovic N, et al. Diagnostic value of the basophil activation test in evaluating Hymenoptera venom sensitisation. Wien Klin Wochenschr. 2009;121:344–348.

    Article  PubMed  Google Scholar 

  25. Scherer K, Weber JM, Jermann TM, et al. Cellular in vitro assays in the diagnosis of Hymenoptera venom allergy. Int Arch Allergy Immunol. 2008;146:122–132.

    Article  PubMed  CAS  Google Scholar 

  26. Ruëff F, Przybilla B, Müller U, et al. The sting challenge test in Hymenoptera venom allergy. Position paper of the Subcommittee on Insect Venom Allergy of the European Academy of Allergology and Clinical Immunology. Allergy. 1996;51:216–225.

    PubMed  Google Scholar 

  27. Franken HH, Dubois AE, Minkema HJ, et al. Lack of reproducibility of a single negative sting challenge response in the assessment of anaphylactic risk in patients with suspected yellow jacket hypersensitivity. J Allergy Clin Immunol. 1994;93:431–436.

    Article  PubMed  CAS  Google Scholar 

  28. Straumann F, Bucher C, Wütrich B. Double sensitization to honeybee and wasp venom: immunotherapy with one or with both venoms? Value of FEIA inhibition for the identification of the cross-reacting IgE antibodies in double-sensitized patients to honeybee and wasp venom. Int Arch Allergy Immunol. 2000;123:268–274.

    Article  PubMed  CAS  Google Scholar 

  29. Wypych JI, Abeyounis CJ, Reisman RE (1989) Analysis of differing patterns of cross-reactivity of honeybee and yellow jacket venom-specific IgE: use of purified venom fractions. Int Arch Allergy Appl Immunol. 89:60–6.

    Article  PubMed  CAS  Google Scholar 

  30. Hemmer W, Focke M, Kolarich D et al. Identification by immunoblot of venom glycoproteins displaying immunoglobulin E-binding N-glycans as cross-reactive allergens in honeybee and yellow jacket venom. Clin Exp Allergy. 2004;34:460–9.

    Article  PubMed  CAS  Google Scholar 

  31. Bonifazi F, Jutel M, Biló BM et al. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy. 2005;60:1459–70.

    Article  PubMed  CAS  Google Scholar 

  32. Modrzyński M, Zawisza E. Possible induction of oral allergy syndrome during specific immunotherapy in patients sensitive to tree pollen. Med Sci Monit. 2005;11: 351–5.

    Google Scholar 

  33. Juarez C, Blanca M, Miranda A et al. Specific IgE antibodies to vespids in the course of immunotherpay with Vespula germanica administered to patients sensitized to Polistes dominulus. Allergy. 1992;47:299–302.

    Article  PubMed  CAS  Google Scholar 

  34. Erzen R, Korosec P, Silar M et al. Carbohydrate epitopes as a cause of cross-reactivity in patients allergic to Hymenoptera venom. Wien Klin Wochenschr. 2009;121:349–52.

    Article  PubMed  CAS  Google Scholar 

  35. Hausmann O, Gentinetta T, Schneider M et al. Double positivity in insect venom allergy – diagnostic approach with basophil activation test. Allergy. 2009;64 (Suppl. 90):140.

    Google Scholar 

  36. Jin C, Focke M, Léonard R, HJarisch R, Altmann F, Hemmer W. Reassessing the role of hyaluronidase in yellow jacket venom allergy. J Allergy Clin Immunol. 2010;125:184–90.

    Google Scholar 

  37. Müller UR, Johansen N, Petersen AB et al. Hymenoptera venom allergy: analysis of double positivity to honey bee and Vespula venom by estimation of IgE antibodies to species-specific major allergens Api m1 and Ves v5. Allergy. 2009;64:543–48.

    Article  PubMed  Google Scholar 

  38. Kosnik M. Anaphylaxis to venom without IgE antibody. Allergy. 2000;55:676–7.

    Article  PubMed  CAS  Google Scholar 

  39. Zidarn M, Kosnik M, Drinovec I. Anaphylaxis after Hymenoptera sting without detectable specific IgE. Acta Dermatovenerol Alp Panonica Adriat. 2007;16:31–3.

    PubMed  Google Scholar 

  40. Diwakar L, Noorani S, Huissoon AP et al. Practice of venom immunotherapy in the United Kingdom: a national audit and review of literature. Clin Exp Allergy. 2008;38:1651–8.

    Article  PubMed  CAS  Google Scholar 

  41. Van der Linden PWG, Hack CE, van der Zwan et al. Preliminary report: complement activation in wasp-sting anaphylaxis. Lancet. 1990;336:904–6.

    Google Scholar 

  42. Oettgen HC, Martin TR, Drazen JM et al. Active anaphylaxis in IgE-deficient mouse. Nature. 1994;370:367–70.

    Article  PubMed  CAS  Google Scholar 

  43. Korosec P, Erzen R, Silar M et al. Basophil responsiveness in patients with insect sting allergies and negative venom-specific immunoglobulin E and skin prick test results. Clin Exp Allergy. 2009;39:1730–7.

    Article  PubMed  CAS  Google Scholar 

  44. Ebo DG, Hagendorens MM, Bridts CH et al. Hymenoptera venom allergy: taking the sting out of difficult cases. J Investig Allergol Clin Immunol. 2007;17:357–60.

    PubMed  CAS  Google Scholar 

  45. Erdmann SM, Sachs B, Kwiecien R et al. The basophil activation test in wasp venom allergy: sensitivity, specificity and monitoring specific immunotherapy. Allergy. 2004;59:1102–9.

    Article  PubMed  CAS  Google Scholar 

  46. Joint Task Force on Practice Parameters; American Academy of Allergy. Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol. 2007;120(Suppl 3):25–85.

    Google Scholar 

  47. Müller UR, Haeberli G. Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol. 2005;115:606–10.

    Article  PubMed  Google Scholar 

  48. Hepner MJ, Ownby DR, Anderson JA et al. Risk of systemic reactions in patients taking beta-blocker drugs receiving allergy immunotherapy injections. J Allergy Clin Immunol. 1990;85:407–11.

    Article  Google Scholar 

  49. Ober AI, MacLean JA, Hannaway PJ. Life-threatening anaphylaxis to venom immunotherapy in a patient taking an angiotensin-converting enzyme inhibitor. J Allergy Clin Immunol. 2003;112:1008–9.

    Article  PubMed  Google Scholar 

  50. Tunon-de-Lara JM, Villanueva P, Marcos M et al. Ace inhibitors and anaphylactoid reactions during venom immunotherapy. Lancet. 1992;340:908.

    Article  PubMed  CAS  Google Scholar 

  51. White KM, England RW. Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy. Ann Allergy Asthma Immunol. 2008;101:426–30.

    Article  PubMed  Google Scholar 

  52. Bilo BM. Venom immunotherapy in hymenoptera venom allergic patients with immunologic diseases and neoplasms. Handouts of EAACI congress, Warsaw 2009.

    Google Scholar 

  53. Schwartz HJ, Golden DBK, Lockey RF. Venom immunotherapy in the Hymenoptera-allergic pregnant patient. J Allergy Clin Immunol. 1990;85:709–712.

    Article  PubMed  CAS  Google Scholar 

  54. Kosnik M, Korosec P, Silar M et al. Wasp venom is appropriate for immunotherapy of patients with allergic reaction to the European hornet sting. Croat Med J. 2002;43:25–7.

    PubMed  Google Scholar 

  55. Erzen R, Bajrovic N, Music E et al. Efficiency of wasp venom specific immunotherapy in patients with allergic reactions to European hornet sting. Allergy. 2009;64 (Suppl. 90): 457.

    Google Scholar 

  56. Freeman TM, Hylander R, Ortiz A et al. Imported fire ant immunotherapy: effectiveness of whole body extracts. J Allergy Clin Immunol. 1992;90:210–5.

    Article  PubMed  CAS  Google Scholar 

  57. Brehler R, Wolf H, Kutting B, Schnitker J et al. Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Immunol. 2000;105:1231–5.

    Article  PubMed  CAS  Google Scholar 

  58. Steiss JO, Jödicke B, Lindemann H. A modified ultrarush insect venom immunotherapy protocol for children. Allergy Asthma Proc. 2006;27:148–50.

    PubMed  Google Scholar 

  59. Goldberg A, Confino-Cohen R. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious. J Allergy Clin Immunol. 2001;107:902–6.

    Article  PubMed  CAS  Google Scholar 

  60. Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol. 2001;108:1027–32.

    Article  PubMed  CAS  Google Scholar 

  61. Mosbech H, Mueller U. Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology. Allergy. 2000;55:1005–10.

    Article  PubMed  CAS  Google Scholar 

  62. Gorska L, Chelminska M, Kuziemski K et al. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy. Int Arch Allergy Immunol. 2008;147:241–5.

    Article  PubMed  CAS  Google Scholar 

  63. Adamic K, Zidarn M, Bajrovic N et al. The local and systemic side-effects of venom and inhaled-allergen subcutaneous immunotherapy. Wien Klin Wochenschr. 2009;121:357–60.

    Article  PubMed  Google Scholar 

  64. La Shell MS, Calabria CW, Quinn JM. Imported fire ant field reaction and immunotherapy safety characteristics: the IFACS study. J Allergy Clin Immunol. 2010;125:1294–9.

    Article  Google Scholar 

  65. Kosnik M, Silar M, Bajrovic N et al. High sensitivity of basophils predicts side-effects in venom immunotherapy. Allergy. 2005;60:1401–6.

    Article  PubMed  CAS  Google Scholar 

  66. Zitnik S, Glavnik V, Avcin T et al. High sensitivity of basophils predict side effect in bee venom immunotherapy in children. Allergy. 2008;63(Suppl 88):642.

    Google Scholar 

  67. Jutel M, Watanabe T, Klunker S et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature. 2001;413: 420–5.

    Article  PubMed  CAS  Google Scholar 

  68. Müller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol. 2001;107:81–6.

    Article  PubMed  Google Scholar 

  69. Rueff F, Wolf H, Schnitker J et al. Specific immunotherapy in honey bee venom allergy: a comparative study using aqueous and aluminium adsorbed preparations. Allergy. 2004;59:589–95.

    Article  PubMed  CAS  Google Scholar 

  70. Bilo B, Roncarolo D, Falagiani P et al. A new potential candidate for ITS of bee venom allergic patients. Allergy. 2009;64 (Suppl. 90):140.

    Google Scholar 

  71. Kontou-Fili K, Filis CI. Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. Allergy. 2009;64:1384–5.

    Article  PubMed  CAS  Google Scholar 

  72. Hunt KJ, Valentine MD, Sobotka AK et al. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med. 1978;299:157–61.

    Article  PubMed  CAS  Google Scholar 

  73. Goldberg A, Confino-Cohen R. Bee venom immunotherapy – How early is it effective. Allergy. 2010;65:391–5.

    Article  Google Scholar 

  74. Golden DB, Kagey-Sobotka A, Lichtenstein LM. Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol. 2000;105:385–90.

    Article  PubMed  CAS  Google Scholar 

  75. Lerch E, Müller UR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol. 1998;101:606–12.

    Article  PubMed  CAS  Google Scholar 

  76. Hafner T, DuBuske L, Kosnik M. Long-term efficacy of venom immunotherapy. Ann Allergy Asthma Immunol. 2008;100:162–5.

    Article  PubMed  Google Scholar 

  77. Peternelj A. Silar M, Erzen R et al. Basophil sensitivity in patients not responding to venom immunotherapy. Int Arch Allergy Immunol. 2008;146:248–54.

    Article  PubMed  Google Scholar 

  78. Joanne NG, Elberink O, Monchy JGR et al. Venom immunotherapy improves health related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol. 2002;110:174–82.

    Article  Google Scholar 

  79. Roesch A, Boerzsoenyi J, Babilas P et al. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population. J Dtsch Dermatol Ges. 2008;6:292–7.

    Article  PubMed  Google Scholar 

  80. Confino-Cohen R, Melamed S, Goldberg A. Debilitating beliefs, emotional distress and quality of life in patients given immunotherapy for insect sting allergy. Clin Exp Allergy. 1999;29:1626–31.

    Article  PubMed  CAS  Google Scholar 

  81. Oude Elberink J, de Monchy J, van der Heide S et al. Venom immunotherapy improves health related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol. 2002;110:174–82.

    Article  PubMed  Google Scholar 

  82. Potier A, Lavigne C, Chappard D et al. Cutaneus manifestations of Hymenoptera and Diptera anaphylaxis: relationship to basal serum tryptase. Clin Exp Allergy. 2009;39:717–25.

    Article  PubMed  CAS  Google Scholar 

  83. Bonadonna P, Zanotti R, Caruso B et al. Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy. J Allergy Clin Immunol. 2008;121:256–257.

    Article  PubMed  CAS  Google Scholar 

  84. Brockow K, Jofer C, Behrendt H et al. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63:226–32.

    Article  PubMed  CAS  Google Scholar 

  85. Müller U. Elevated baseline serum tryptase, mastocytosis and anaphylaxis. Clin Exp Allergy. 2009;39:620–2.

    Article  PubMed  Google Scholar 

  86. Bonadonna P, Perbellini O, Passalacqua G et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol. 2009;123:680–686.

    Article  PubMed  CAS  Google Scholar 

  87. Fricker M, Helbling A, Schwartz L et al. Hymenoptera sting anaphylaxis and urticaria pigmentosa: Clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol. 1997;100:11–15.

    Article  PubMed  CAS  Google Scholar 

  88. Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol. 2001;108:1027–1032.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Clinic of Respiratory and Allergic Diseases, Golnik, Kranj, Slovenia

    Mitja Kosnik

Authors
  1. Mitja Kosnik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Korosec
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mitja Kosnik .

Editor information

Editors and Affiliations

  1. Harvard Medical School, Ambulatory Center, Brigham and Women’s Hospital, Boyleston Street, Route 9 850, Chestnut Hill, 02467, Massachusetts, USA

    Mariana C. Castells

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Kosnik, M., Korosec, P. (2011). Hymenoptera-Induced Hypersensitivity Reactions and Anaphylaxis. In: Castells, M. (eds) Anaphylaxis and Hypersensitivity Reactions. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-951-2_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-951-2_12

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60327-950-5

  • Online ISBN: 978-1-60327-951-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation